A Review on -A Rare Disorder of Waldenstrom’s Macroglobulinemia
About Authors:
Ms. Shilpa G. Lodha1, Vanita Nimje2, Ramzan Virani3
1 Department of Biotechnology,
Agnihotri College of Science, Ram Nagar,
Wardha 442001, India.
2 Department of Biotechnology,
Jankievi Bajaj college, Arvi Naka,
Wardha 442001, India.
3 Department of Biology,
Shivramji Moghe College of Science,
Panharkawada- 445 302, India.
Abstract
Many types of Cancer and Malingancy are known, in that Waldenstrom’s macroglobulinemia is rare cancer of an uncommon lymphoproliferative disorder characterized primarily by bone marrow infiltration and IgM monoclonal gammopathy. It should be considered a distinct clinicopathological entity rather than a clinical syndrome secondary to IgM secretion. The concentration of monoclonal IgM can vary widely in Waldenstrom’s macroglobulinemia and it is not possible to define a concentration that reliably distinguishes it from monoclonal gammopathy of undetermined significance (MGUS). Besides having lots of diagnosis method, there is no single accepted treatment for Waldenstrom’s macroglobulinemia. Commonly used treatment includes the monoclonal antibody rituximab, sometimes in combination with chemotherapeutic drugs such as chlorambucil, cyclophosphamide, or vincristine or with thalidomide. We have to find out the successful and low cost methods to cure Waldenstrom’s macroglobulinemia.